Opendata, web and dolomites

NeuroProtect

Novel Drug Therapy with Potential to Cure Neuro-Degenerative Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroProtect project word cloud

Explore the words cloud of the NeuroProtect project. It provides you a very rough idea of what is the project "NeuroProtect" about.

faster    investors    founders    compound    market    amyotrophic    cure    pharma    healing    socioeconomic    efficiency    anti    herb    axon    switzerland    worked    sclerosis    significance    planning    perform    proven    therapies    route    drugs    plan    diseases    select    neurons    neurodegenerative    physician    approval    commercialization    honeywell    guan    co    parkinson    vitro    alzheimer    remarkable    business    whilst    trials    outgrowth    pharmaceutical    yuhong    game    relatively    economic    fastest    patient    15m    pd    until    gives    damaged    ip    outlicense    team    rescuing    led    companies    advisors    burden    refund    rare    alone    mouse    preliminary    dr    ad    tests    david    als    company    suffer    neuroprotect    finish    natural    reduce    10m    changer    showed    drug    strategy    royalties    hp    over    models    neuro    global    clinical    extensive    human    succeed    orphan    positions    pay    300m    reverse    apoptotic    lifetime    neuronal    japan    primary    disease    neuroprotective    dong    symptoms    phase    standard    industry    total    treat    europeans    lateral    update    multinational   

Project "NeuroProtect" data sheet

The following table provides information about the project.

Coordinator
SUNREGEN HEALTHCARE AG 

Organization address
address: ROBINIENWEG 51
city: Reinach
postcode: 4153
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.sunregen.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUNREGEN HEALTHCARE AG CH (Reinach) coordinator 50˙000.00

Map

 Project objective

Over 10M Europeans suffer from neurodegenerative diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Whilst there are many drugs that treat symptoms of these diseases, there are no therapies that can reverse or cure them. Our novel compound NeuroProtect has the potential to be a game changer by healing damaged neurons. NeuroProtect is a natural herb-derived compound with remarkable neuroprotective, neuro-rescuing, anti-apoptotic, and axon-outgrowth effects in mouse primary neuronal and human neuronal models. We have proven the compound’s efficiency in preliminary in-vitro tests. To take NeuroProtect to market fastest, we will focus on ALS that where we can use the orphan drug route and get clinical approval faster. This gives us an immediate target market of €300M per year in Europe, the US, Japan and Switzerland alone. Although ALS is relatively rare, the socioeconomic significance of the disease is extensive: a recent study showed that total lifetime costs for ALS were €1.15M per patient. NeuroProtect can therefore contribute to reduce the global economic burden of ALS. We are planning to take the standard route for commercialization in pharma industry: take the compound through pre-clinical studies, Phase I and Phase II clinical trials and then outlicense to a large pharma company who will refund our cost until they finish the Phase III trials and then pay us royalties. Our team is led by two experienced co-founders: Dr. Yuhong Dong, who has worked for a multinational pharmaceutical company for over 10 years as well as a physician for 4 years, and David Guan, who has over 10 years of management positions at multinational companies (HP, Honeywell). We are also supported by experienced advisors and investors to help us succeed. We are planning to use the Phase 1 funding to select our pre-clinical study partners, perform a market assessment, assess our IP strategy and update our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPROTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROPROTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More